Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
BD (NYSE: BDX) has entered into a collaboration with Biocorp to enhance self-administered drug therapies through connected technology. The partnership aims to integrate Biocorp's Injay® technology with BD's UltraSafe Plus™ Passive Needle Guard, allowing biopharmaceutical manufacturers to capture and transmit injection data. This innovation is expected to improve patient adherence to injectable drugs. The connected drug delivery market is projected to grow significantly as digital technologies and self-administered therapies become more prevalent.
BD (Becton, Dickinson and Company) will announce its fiscal 2022 fourth quarter and full year financial results on November 10, 2022, at approximately 6:30 a.m. ET. The announcement will provide summarized financial information for the quarter and full year ending on September 30, 2022.
An audio webcast will follow at 8 a.m. ET on the same day to discuss the results and company operations. Investors can access the release and the webcast on BD's investor relations website.
Summary not available.
BD (Becton, Dickinson and Company) has announced a grant of $360,000 to six U.S. free clinics as part of its Point-of-Care, Enhancing Clinical Effectiveness initiative. This program, established in 2017, has supported 27 clinics across 20 states with a total of $2.6 million. The initiative aims to improve health outcomes in underserved communities by providing diagnostic testing capabilities for common health issues, impacting over 16,500 patient visits this year. Collaborating partners include Heart to Heart International and the National Association of Free and Charitable Clinics.
BD (Becton, Dickinson and Company) has launched the BD® Research Cloud, a cloud-based software designed to enhance flow cytometry workflows. This integrated ecosystem aids scientists in optimizing panel design, collaboration, and data analysis across various research fields like immunology and oncology. Developed by the creators of FlowJo™ Software, it streamlines the workflow by connecting instruments to data analysis, enabling more efficient experiments and faster insights. The platform is built on a reliable cloud infrastructure and aims to support future advancements in flow cytometry research.
BD announced the global availability of its new molecular PCR assay for monkeypox virus, developed in collaboration with CerTest Biotec. This assay is intended for research use only and is now accessible worldwide, including in the U.S. BD is also preparing to submit a clinical test for emergency use authorization. The BD MAX™ System, which supports this assay, features rapid nucleic acid extraction and PCR capabilities. The new test aims to enhance monkeypox research amidst the ongoing public health emergency.
LivaNova PLC (NASDAQ: LIVN) announced the appointment of Brooke Story to its Board of Directors, effective September 15, 2022. Story brings over 20 years of experience in medical technology, currently serving as Worldwide President, Integrated Diagnostic Solutions at BD (NYSE: BDX). She previously held leadership roles at Medtronic, enhancing her expertise in the industry. The Board's Chair, William Kozy, emphasized Story's capability in fostering talent and delivering economic value, which is expected to support LivaNova's growth and innovation strategies.
BD (Becton, Dickinson and Company) has launched the BD EffivaxTM Glass Prefillable Syringe, designed in collaboration with leading pharmaceutical firms. This next-generation syringe aims to enhance vaccine manufacturing efficiency by addressing critical aspects such as processability, contamination, and integrity. With about 70% of top biopharmaceutical companies relying on BD, this innovation is set to meet increasing global demand for prefillable syringes, particularly due to the growth in vaccine pipelines. Additionally, BD continues to invest $1.2 billion in enhancing its manufacturing capacity for these products.
BD (Becton, Dickinson and Company) has announced the promotion of Mike Garrison to EVP and President of the Medical segment, and Rick Byrd to EVP and President of the Interventional segment, effective Sept. 6. Both leaders bring extensive experience from their previous roles within the company. Garrison will focus on advancing innovation and portfolio strategy, while Byrd will continue to drive growth and operational excellence in his segment. The decision follows the upcoming departure of Simon Campion, who is leaving for another executive role.
BD (Becton, Dickinson and Company) will present at the Wells Fargo 2022 Healthcare Conference on September 7, 2022, at 12:30 PM Eastern Time. Interested parties can access the live webcast via the BD investor relations website, with a replay available afterwards. BD is a leading global medical technology company focused on enhancing healthcare quality through innovation. With a strong commitment to improving medical discovery and diagnostics, BD operates globally, aiming to tackle pressing health challenges.